KYNB
Kyntra Bio, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$8.55
+0.71%Year over year
Reported trailing growth
- Revenue
- +106.3%
- EBITDA
- +27.2%
- EBIT
- +62.3%
- EPS
- +3782.9%
- Free cash flow
- -60.6%
- Operating cash flow
- -62.3%
Forward estimates
Based on analyst estimates
- Revenue
- +45.8%
- EBITDA
- +52.2%
- EPS
- —
Three-year CAGR
- Revenue
- -64.2%
- EBITDA
- +59.6%
- EBIT
- +69.5%
- Net income
- +485.6%
- EPS
- +9552.1%
- Free cash flow
- +96.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026